Absorption Systems Announces Major Expansion of Facilities
EXTON, Pa., Sept. 27, 2017 /PRNewswire/ -- Absorption Systems, a global leader in the advancement of translational medicine, announces a major expansion of two research facilities; near Philadelphia, PA and San Diego, CA. The expansion is driven by sustained demand for the company's high quality contract services to pharmaceutical and biotechnology companies, as well as growing demand for the company's contract manufacturing and commercial release testing in the nascent gene therapy and cell therapy markets.
At both the California and Pennsylvania sites, the company's footprint will grow by nearly 50%, with construction and outfitting of new laboratories and offices set for completion in September and October. New hires will increase headcount by approximately 20%.
Absorption Systems recently branded its subsidiary, a dedicated cGMP (current Good Manufacturing Practice) testing facility for gene and cell therapy products, as ACF Bioservices(TM). The company's strength in gene and cell therapy has been heavily driven by customer demand for regulatory-compliant solutions over the past two to three years and is a natural outgrowth of the parent company's long-standing leadership in developing GLP (Good Laboratory Practice)-compliant in vitro cell-based models to predict the in vivo behaviour of therapeutics.
Patrick Dentinger, President and CEO, commented that "This current expansion of the company is a result of a strategic plan for sustained incremental growth in a number of different growing areas, in particular our initiative into potency testing for gene and cell therapy products."
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. IDAS2, a novel in vitro test system for simultaneous screening of drug absorption and dissolution, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for formulation assessment. Absorption Systems, with facilities near Philadelphia, PA, in San Diego, CA, and in Panama, serves customers throughout the world. For information on the company's comprehensive contract services, applied research programs, and proprietary test systems, please visit www.absorption.com.
About ACF Bioservices
ACF Bioservices (an Absorption Systems company) has the expertise and relevant experience needed to provide analytical support for gene and cell therapy products through every stage of development. Potency assays are on the critical path, and ACF offers de novo development, optimization, qualification, validation, and cGMP-compliant final product and product release testing services for both allogenic and autologous therapies. We have the capability to develop both in vitro and in vivo models to predict human outcomes and establish correlations between animal studies and in vitro cell-based assays. Our fully compliant facilities and studies have been inspected by the FDA, USDA, and AAALAC. ACF has over 20 years of business operating expertise developing proprietary assays, combining our skills in cell and molecular biology, assay development and validation, bioanalytical and immunochemical quantitation, statistical analysis, and regulatory affairs in a single-source collaboration. Please contact ACF Bioservices for additional information at acfbioservices.com.
Chris Bode
Absorption Systems
1-610-280-1451
cbode@absorption.com
www.absorption.com
View original content:http://www.prnewswire.com/news-releases/absorption-systems-announces-major-expansion-of-facilities-300526782.html
SOURCE Absorption Systems
